Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Issue 1 (December 2016) - Laszlo, George; Alonzo, Todd; Gudgeon, Chelsea; Harrington, Kimberly; Kentsis, Alex; Gerbing, Robert; Wang, Yi-Cheng; Ries, Rhonda; Raimondi, Susana; Hirsch, Betsy; Gamis, Alan; Meshinchi, Soheil; et al.